| Market Cap | 10.39M | P/E | - | EPS this Y | 7.00% | Ern Qtrly Grth | - |
| Income | -22.27M | Forward P/E | -0.63 | EPS next Y | 30.20% | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -7.00% |
| Dividend | N/A | Price/Book | 0.22 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | 2.00 | Quick Ratio | 2.71 | Shares Outstanding | 1.35M | 52W Low Chg | 76.00% |
| Insider Own | 0.58% | ROA | -24.98% | Shares Float | 1M | Beta | 1.39 |
| Inst Own | 2.44% | ROE | -59.06% | Shares Shorted/Prior | 90.98K/3.99K | Price | 0.69 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 749,319 | Target Price | 100.00 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 127,579 | Change | 5.68% |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Jun 07 | Buy | 0.6931 | 14,000 | 9,703 | 250,000 | 06/08/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Jun 06 | Buy | 0.6328 | 26,000 | 16,453 | 236,000 | 06/07/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Feb 10 | Buy | 1.043 | 25,000 | 26,075 | 210,000 | 02/13/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Feb 02 | Buy | 0.9405 | 25,000 | 23,512 | 185,000 | 02/03/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Jan 25 | Buy | 0.873 | 25,000 | 21,825 | 160,000 | 01/26/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Jan 20 | Buy | 0.7482 | 25,000 | 18,705 | 135,000 | 01/23/23 |
| SHALLCROSS STEVEN A | CEO and CFO CEO and CFO | Dec 29 | Buy | 0.437 | 100,000 | 43,700 | 110,000 | 01/03/23 |